Incyte Corporation

60.56
0.01 (0.02%)
At close: Apr 01, 2025, 3:07 PM

Company Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.

The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.

In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma.

Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer.

It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.

The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation
Incyte Corporation logo
Country United States
IPO Date Nov 4, 1993
Industry Biotechnology
Sector Healthcare
Employees 2,617
CEO Herve Hoppenot

Contact Details

Address:
1801 Augustine Cut-Off
Wilmington, Delaware
United States
Website https://www.incyte.com

Stock Details

Ticker Symbol INCY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000879169
CUSIP Number 45337C102
ISIN Number US45337C1027
Employer ID 94-3136539
SIC Code 8731

Key Executives

Name Position
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis M.B.A. Executive Vice President & Chief Financial Officer
Ben Strain Head of Investor Relations
Dr. Pablo J. Cagnoni M.D., Ph.D. President and Head of Research & Development
Dr. Steven H. Stein M.D. Executive Vice President & Chief Medical Officer
Michael James Morrissey Executive Vice President & Head of Global Technical Operations
Pamela M. Murphy Vice President of Investor Relations & Corporate Communications
Paula J. Swain Executive Vice President of Human Resources
Sheila A. Denton J.D. Executive Vice President, General Counsel & Corporate Secretary
Thomas Tray Vice President of Finance, Chief Accounting Officer & Controller

Latest SEC Filings

Date Type Title
Mar 27, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 06, 2025 4 Filing
Feb 28, 2025 4 Filing
Feb 10, 2025 S-3ASR Automatic shelf registration statement of securiti...
Feb 10, 2025 10-K Annual Report
Feb 10, 2025 8-K Current Report
Feb 03, 2025 4 Filing
Feb 03, 2025 4 Filing
Jan 22, 2025 4 Filing